Abstract：Objective To investigate the expression of the chemokine receptor 4 (CXCR4) in triple negative breast cancer and its relationship with the prognosis of recurrence and metastasis. Methods A total of 160 cases of triple negative breast cancer from May 2015 to January 2018 in our hospital were collected, immunohistochemistry was used to analyze the expression of CXCR4. The clinicopathological features and the relationship between CXCR4, time of disease progression and total survival were analyzed. Results There were significant differences in the age, axillary lymph nodes and disease-free survival (DFS) of CXCR4 group (P＜0.001). There were shorter DFS with age ≤45 years old, axillary lymph node positive and CXCR4 positive. The overall survival (OS) of CXCR4 positive patients was shorter than that of CXCR4 negative patients. Conclusion CXCR4 overexpression is not only a marker of tumor invasiveness, but also a marker of poor prognosis in triple negative breast cancer patients.
Romagnolo DF.Epigenetic Activation of BRCA1 by Genistein In Vivo and Triple Negative Breast Cancer Cells Linked to Antagonism toward Aryl Hydrocarbon Receptor[J].Nutrients，2019，11（11）：2559.
[2]
Bergin ART，Loi S.Triple-negative breast cancer：recent treatment advances[J].F1000Res，2019，8：F1000 Faculty Rev-1342.
[3]
D′Alterio C，Buoncervello M，Ieranò C，et al.Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1[J].J Exp Clin Cancer Res，2019，38（1）：432.
[4]
Thakur V，Kutty RV.Recent advances in nanotheranostics for triple negative breast cancer treatment[J].J Exp Clin Cancer Res，2019，38（1）：430.
Ferreira F.CXCL12-CXCR4 axis in feline mammary carcinoma[J].Aging （Albany NY），2017，9（12）：2457-2458.
[9]
Duda DG，Kozin SV，Kirkpatrick ND，et al.CXCL12 （SDF1alpha）-CXCR4/CXCR7 pathway inhibition：an emerging sensitizer for anticancer therapies?[J].Clin Cancer Res，2011，17（8）：2074-2080.
[10]
Kijowski J，Baj-Krzyworzeka M，Majka M，et al.The SDF-1-CXCR4 axis stimulates VEGF secretion and activates integrins but does not affect proliferation and survival in lymphohematopoietic cells[J].Stem Cells，2001，19（5）：453-466.
[11]
Nguyen KTP，Druhan LJ，Avalos BR，et al.CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration[J].Cellular Signalling，2020，66：109 488.
[12]
Dayer R，Babashah S，Jamshidi S，et al.Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive breast carcinoma：a potent biomarker predicting lymph node metastasis[J].J Cancer Res Ther，2018，14（2）：345-350.
Chu QD，Panu L，Holm NT，et al.High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome[J].J Surg Res，2010，159（2）：689-695.
[14]
Shanmugam MK，Ahn KS，Hsu A，et al.Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis[J].Front Pharmacol，2018，9：1294.
[15]
Yang M，Zeng C，Li P，et al.Impact of CXCR4 and CXCR7 knockout by CRISPR/Cas9 on the function of triple-negative breast cancer cells[J].Onco Targets Ther，2019，12：3849-3858.
[16]
Guembarovski AL，Guembarovski RL，Hirata BKB，et al.CXCL12 chemokine and CXCR4 receptor：association with susceptibility and prognostic markers in triple negative breast cancer[J].Mol Biol Rep，2018，45（5）：741-750.
[17]
Howard CM，Bearss N，Subramaniyan B，et al.The CXCR4-LASP1-eIF4F Axis Promotes Translation of Oncogenic Proteins in Triple-Negative Breast Cancer Cells[J].Front Oncol，2019，9：284.
京公网安备 11010502046607号